Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Pharma researcher charged with theft of trade secrets  

By Brian Buntz | January 19, 2021

Image from Bill Oxford via Unsplash

A former director of medical and scientific affairs at Merck (NYSE:MRK) faces criminal charges in federal court in New Jersey for allegedly stealing and transmitting trade secrets.

Shafat A. Quadri has been released on $100,000 unsecured bond. He was most recently employed at AstraZeneca (NSDQ:AZN).

The single count of trade secret theft carries a maximum potential penalty of up to 10 years in prison and a fine as high as $250,000, or double the total financial gain or loss, according to Rachael A. Honig, acting U.S. attorney for the District of New Jersey.

The complaint describes Quadri’s former employer as “Company 1,” stating that the organization reached out to the FBI in Oct. 2019 to report suspicious activity regarding its sensitive intellectual property. Quadri had been employed at that company until Sept. 30, 2019.

The suit alleges that Quadri used his email account to send at least 12 sensitive documents to private email accounts. Some of those documents pertained to an immunotherapy drug.

Company 1 used a network data loss prevention tool to identify 106 documents that Quadri allegedly sent to private email addresses. Some of the documents were outside of Quadri’s area of specialty at the company.


Filed Under: Drug Discovery, Drug Discovery and Development
Tagged With: AstraZeneca plc, immunotherapy, intellectual property, Merck, trade secrets
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Diversity
Making diversity in clinical research more than a talking point
psychedelic medicine discussed at SXSW
5 headwinds and 5 tailwinds for psychedelic medicine
lab microscope
Accelerating R&D with FAIR data
Kallyope
Kallyope’s focus on the gut-brain axis yields a diverse portfolio

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50